IQVIA HOLDINGS INC. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
IQVIA HOLDINGS INC. (IQV) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $2.30 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-04-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2015-04-29
- IQVIA HOLDINGS INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2015-03-31 was $2.30M.
- IQVIA HOLDINGS INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2014 was $2.30M, a 0.00% change from fiscal 2013.
- IQVIA HOLDINGS INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2013 was $2.30M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 3 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|---|
| 2015-03-31 | $2.30M 10-Q · filed 2015-04-29 | |
| 2014-12-31 | $2.30M 10-K · filed 2015-02-12 | |
| 2013-12-31 | $2.30M 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |